Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Public ClinicalTrials.gov record NCT00577577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1
Study identification
- NCT ID
- NCT00577577
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Insmed Incorporated
- Industry
- Enrollment
- 69 participants
Conditions and interventions
Conditions
Interventions
- rhIGF-I/rhIGFBP-3 Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 21 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2007
- Primary completion
- Dec 28, 2008
- Completion
- Dec 28, 2008
- Last update posted
- Jan 5, 2022
2007 – 2008
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine Medical Center; MDA, ALS and Neuromuscular Center | Orange | California | 92868 | — |
| University of California, Davis | Sacramento | California | 95817 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Washington University Medical School | St Louis | Missouri | 63110 | — |
| University of Rochester, Neuromuscular Disease Center | Rochester | New York | 14642 | — |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | — |
| Oregan Health and Science University | Portland | Oregon | 97239 | — |
| Universit of Texas Medical Branch | Galveston | Texas | 77555-0539 | — |
| University of Texas Health Science Center | San Antonio | Texas | 78229 | — |
| University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00577577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2022 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00577577 live on ClinicalTrials.gov.